Visugromab in Cachexia International Trial
Recruiting now · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Cancer-associated Cachexia
In brief
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Key facts
- Study ID
- NCT07112196
- Run by
- CatalYm GmbH
- People needed
- 518
- Starts
- 2026-04-16
- Expected to finish
- 2030-12-01
- Last updated by the study team
- 2026-07-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Weight loss
- Advanced cancer
You may not qualify if…
- Participation in another interventional clinical trial, receipt of any investigational therapy or use of any investigational device within 4 weeks prior to screening and between screening and the first dose of investigational product
Where it is running
- Clermont Oncology Center — Clermont, Florida, United States (enrolling)
- Mid Florida Hematology and Oncology Centers — Orange City, Florida, United States (enrolling)
- Astera Cancer Care — East Brunswick, New Jersey, United States (enrolling)
- Cleveland Clinic Avon Hospital — Avon, Ohio, United States (enrolling)
- Cleveland Clinic (Main Campus) — Cleveland, Ohio, United States (enrolling)
- Cleveland Clinic Fairview Hospital — Fairview, Ohio, United States (enrolling)
- Cleveland Clinic Hillcrest Hospital — Mayfield Heights, Ohio, United States (enrolling)
- Specialized Hospital for Active Treatment in Oncology — Haskovo, Bulgaria (enrolling)
- Medical Centre Futuremeds Plovdiv — Plovdiv, Bulgaria (enrolling)
- University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna-ISUL — Sofia, Bulgaria (enrolling)
- Complex Oncology Center - Vratsa EOOD — Vratsa, Bulgaria (enrolling)
- Multiscan, s.r.o., Nemocnice Horovice — Hořovice, Czechia (enrolling)
- Fakultni nemocnice Hradec Kralove — Hradec Králové, Czechia (enrolling)
- Fakultni nemocnice v Motole — Prague, Czechia (enrolling)
- CHRU de Brest - Hopital Morvan — Brest, France (enrolling)
- Léon Bérard Center (Centre Léon Bérard) — Lyon, France (enrolling)
- Centre Paul Strauss — Strasbourg, France (enrolling)
- Johanniter Krankenhaus Bonn — Bonn, Germany (enrolling)
- University Hospital Carl Gustav Carus Dresden (Universitätsklinikum Carl Gustav Carus Dresden) — Dresden, Germany (enrolling)
- Centro Riferimento Oncologico - Aviano — Aviano, Italy (enrolling)
- ASST degli Spedali Civili di Brescia — Brescia, Italy (enrolling)
- Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant'Anna — Ferrara, Italy (enrolling)
- IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l. — Meldola, Italy (enrolling)
- Centro Ricerche Cliniche di Verona — Verona, Italy (enrolling)
- Eastern Connecticut Hematology & Oncology — Norwich, Connecticut, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.